Replimune (REPL) Non-Current Deffered Revenue (2018 - 2019)
Replimune's (REPL) quarterly Non-Current Deffered Revenue came in at $24000.0 in Q1 2019, down 53.85% year-on-year from $52000.0 in Q1 2018, and down 85.71% quarter-over-quarter from $168000.0 in Q4 2018.
Replimune (REPL) Non-Current Deffered Revenue (2018 - 2019) Analysis & Trends
Replimune has disclosed Non-Current Deffered Revenue across 2 years of filings, most recently posting $24000.0 for Q1 2019.
- Non-Current Deffered Revenue for Q1 2019 came in at $24000.0, down 53.85% year-over-year; the trailing twelve-month figure through Mar 2019 was $24000.0 (down 53.85% YoY), and the FY2019 annual result was $24000.0, down 53.85% from the prior year.
- Non-Current Deffered Revenue came in at $24000.0 for Q1 2019 at Replimune, down from $168000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $168000.0 in Q4 2018 to a low of $24000.0 in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Replimune | 780.01 Mn | 510.88 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 24,000.00 |
| Dec 31, 2018 | 168,000.00 |
| Sep 30, 2018 | 36,000.00 |
| Jun 30, 2018 | 43,000.00 |
| Mar 31, 2018 | 52,000.00 |